By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    health benefits of taking a vacation to reduce stress
    Relaxing European Destinations to Reduce Stress Risks to Health
    October 11, 2021
    pain management tips
    Managing Pain Differently: Alternative Pain Management Techniques
    January 12, 2022
    5 Ways to Promote Wellness in Your Home
    April 12, 2022
    Latest News
    Beyond the Clinic: Medical Surveys Are a Roadmap to Passive Income for Doctors
    September 23, 2023
    5 Self-Care Habits to Help You Live an A+ Life
    September 21, 2023
    Keep Employees Safe & Healthy By Reducing Warehouse Injuries
    September 20, 2023
    What is Pneumonia? Causes, Treatment, and Care
    September 19, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    TDWI’s Kevin Campbell Discusses Aspirin and Tylenol
    May 3, 2013
    Questions for FDA, NIH on Failure to Publish Clinical Trial Data
    February 16, 2012
    Image
    Can Digital Health Prevent You from a Premature Death?
    June 29, 2013
    Latest News
    Job Seekers with Disabilities Should at Health Insurance Benefits
    September 12, 2023
    Reasons That Drug Prices Are Rising to Unsustainable Levels
    September 12, 2023
    How Revenue Lifecycle Management Helps Healthcare Providers to Optimize Business Operations
    September 6, 2023
    The Hidden Benefits of Practice Exams for Medical Professionals
    September 6, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods in Treatment of Alzheimer’s Disease
Share
Sign In
Notification Show More
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods in Treatment of Alzheimer’s Disease
Public Health

Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods in Treatment of Alzheimer’s Disease

HerinaAyot
Last updated: 2012/02/11 at 10:01 AM
HerinaAyot
Share
4 Min Read
SHARE

Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid.

Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid. Federal funding of Alzheimer’s research is an inadequate $450 million, and does not reflect the escalating national epidemic of Alzheimer’s Disease.

On January 4, 2011, the National Alzheimer’s Project Act was signed into law by President Obama after having been passed unanimously in both the Senate and House of Representatives. This is a major victory for the Alzheimer’s Association and its advocates – as well as for the nation. The key now is to ensure this act is implemented. Intellect Neurosciences is on the right track.

Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer’s and other neurological diseases has filed two United States, and one international patent application regarding passive and active immunotherapy approaches targeting abnormal forms of tau protein that lead to death of nerve cells in Alzheimer’s disease.

More Read

9 Things You Need to Know About Medicare

5 Compelling Reasons to See a Functional Medicine Doctor
Examining Whether Socialized Medicine Will Ever Happen in America
Creating an effective care plan: The ultimate guide
7 Incredibly Important Benefits of Purchasing Health Insurance

“These new patent filings continue to demonstrate our leadership in translational Alzheimer’s research and ongoing commitment to develop improved next-generation drug products,” said Dr. Daniel G. Chain, Intellect’s chairman & CEO. “We are encouraged by the results of two recent studies conducted by independent groups from Columbia University and Harvard Medical School suggesting that tau may cause Alzheimer’s disease to spread through the brain. Their findings indicate that an antibody approach may halt that spread, which supports our strategy of a combined vaccine against beta amyloid and delta tau that may potentially eliminate the disease.”

Intellect Neuroscience is investigating the combination of its new technology for which it has filed the recent patents with its RECALL-VAX active vaccine platform, which was originally developed to target neoepitopes in amyloid beta. The company has manufactured a combination test vaccine from its RECALL-VAX platform, RV03, to target both beta amyloid and delta tau, which are increasingly understood to act in the pathogenesis of Alzheimer’s disease. The company is embarking on a series of preclinical studies with RV03, using brain imaging and other translational tools to test both safety and efficacy to facilitate design of future clinical trials.

The company is currently developing products based on three platform technologies: ANTISENILIN® is Intellect’s Alzheimer’s beta amyloid monoclonal antibody platform technology, which underlies a product in Phase 3 clinical trials licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, which is being developed by the company as an antibody dug conjugate (ADC). IN-N01-OX2 is the first candidate to emerge from the company’s CONJUMAB-A platform technology, that has poten neuroprotective properties both as an antioxidant and inhibitor of protein aggregation. RECALL-VAX is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01 and RV02, which target beta amyloid and delta tau protein, respectively, and RV03 which is a combination of the two.

The company recently licensed OX1, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich’s Ataxia and other neurodegenerative diseases.

Intellect Neurosciences recently presented at the 5th annual OneMedForum San Francisco 2012 and at 2012 BIO Asia International Partnering Conference.

 

TAGGED: Alzheimers, Intellect Neurosciences

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
HerinaAyot February 11, 2012
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Can Anyone Explain This?
Next Article Health Insurance For Same Sex Couples

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

Anxiety Disorder
The Importance of Nutrition in Anxiety Disorder Treatment
Anxiety September 24, 2023
spinal health
How to Advocate For Your Spinal Health In A Healthcare Setting: Strategies From Dr. Brandon Claflin
News September 24, 2023
Medical Surveys
Beyond the Clinic: Medical Surveys Are a Roadmap to Passive Income for Doctors
Health September 23, 2023
tips for neurodivergent people being pulled over
Tips for People with Neurodivergent Disorders Being Pulled Over
News September 21, 2023

You Might also Like

healthcare influencers
Public Health

The Impact of Health Influencers on Public Health

July 18, 2023
Health carePublic Health

Do You Need Life Insurance? What Does It Cover?

December 23, 2022

Do I Qualify for Social Security Disability Benefits if I Got Injured on My Way to Work?

August 23, 2022
Right Medicare Supplement Plan
Health carePublic Health

What If You Need Emergency Care and Don’t Have Insurance?

February 15, 2022
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?